Foslevodopa

DB16683ApprovedSmall molecule

Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Advanced...

Chemical structure of Foslevodopa
Mechanism
Curator reviewed
Formula / weight
C9H12NO7P · 277.169 g/mol (avg)
First approval
Canada, 2023 · United States, 2022
Also known as
3-hydroxy-O-phosphono-L-tyrosine · Levodopa-4'-monophosphate
Code names
ABBV-951

Resolves to

Compound
UNII37NQZ0J76ICAS97321-87-4ChEMBLCHEMBL4594379ChEBI192509
Clinical / RWD
RxNorm2695775ATCN04BA07
Structure
InChIKeyYNDMEEULGSTYJT-LURJTMIESA-NSMILESN[C@@H](CC1=CC=C(OP(O)(O)=O)C(O)=C1)C(O)=O
Targets
P08588ADRB1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
48Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Marketed productsAcross 3 countries and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 4 drug categories
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Foslevodopa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In